Multi-component pharmaceutical compositions perform various functions and confer various benefits, but often with reduced benefits resulting from interference and cancellation effects between components. To avoid this problem multi-component pharmaceutical compositions can include three separate compositions, each differing by at least one component, or in which all components differ. Doses from each composition are taken over a given period of time, such as a day. One dose from a first composition is taken in the morning, a dose from a second composition is taken at mid-day, and a dose from a third composition is taken at night, for example. Methods of preventing, treating, and mitigating various diseases and disorders, including Alzheimer's disease and related disorders, autism spectrum disorders, cancer, and thrombosis also appear.

A nanoparticle comprising a keratin polypeptide and at least one lipophilic active ingredient, wherein the at least one lipophilic active ingredient is non-covalently bound to the keratin polypeptide and can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical, the keratin polypeptide being water-soluble; optionally, the nanoparticle further comprises at least one hydrophilic active ingredient non-covalently bound to the keratin polypeptide, which can be e.g. a therapeutic or diagnostic agent, a nutraceutical, a cosmetic ingredients, a dye or a cosmeceutical.

Disclosed is a composition including controlled release particles, wherein each of the controlled release particles includes: (a) a core including at least one hydrophobic active ingredient; and (b) a wall at least partially surrounding the core and including the reaction products of: (i) an organofunctional silane; (ii) an epoxy; (iii) an amine; (iv) an isocyanate; (v) an epoxide curing agent; (vi) a basified biodegradable resin; (vii) a pre-reacted natural material resin; (viii) a pre-reaction product of polyisocyanate; wherein the controlled release particles are effective to retain the at least one hydrophobic active ingredient upon exposure to water and effective to release the at least one hydrophobic active ingredient in response to friction. A method for preparing the composition is also disclosed.

An application of a transgenic stem cell-derived exosome in preparing a medicament or whitening cosmetic is provided. In the present disclosure, miR-27b-3p is transfected into an epidermal stem cell, and a transgenic stem cell-derived exosome is harvested. It is experimentally verified that the exosome can inhibit the expression of PIK3R3 protein in melanocytes and the proliferation and migration of melanocytes; and safety experiments further demonstrate the safety of the exosome. Therefore, corresponding medicaments or cosmetics prepared from the exosome have excellent medicinal and cosmetic application prospects.

The present invention provides a composition for treating or preventing skin pigmentation, which contains fibroblasts as an active ingredient, wherein the fibroblasts are those fibroblasts which are less damaged than fibroblasts localized in a site where the skin pigmentation occurs, and the composition is characterized by being intended to be applied to a site where the pigmentation occurs or a dermis tissue around the site.

The present invention provides a composition for treating or preventing skin pigmentation, which contains fibroblasts as an active ingredient, wherein the fibroblasts are those fibroblasts which are less damaged than fibroblasts localized in a site where the skin pigmentation occurs, and the composition is characterized by being intended to be applied to a site where the pigmentation occurs or a dermis tissue around the site.

Provided is a method for efficiently culturing dermal papilla cells while maintaining an ability to induce hair follicles. A method for culturing dermal papilla cells in the presence of at least one selected from the group consisting of EMILIN and a fragment thereof.

Disclosed are treatment mesenchymal stem cell growth factor compositions and methods of their use to treat skin disorders, hair greying, baldness, and erectile dysfunction as well as their use in skin color/ethnic specific cosmetic and skin treatments. In some aspects, the treatment target SNPs specific to the hair color, skin color, skin type, hair type, race, ethnicity, and/or response to testosterone.

A natural human shaker hair is offered to be efficiently applied to the balding spots and thinning areas of a user's scalp. The shaker hair comprises 100% natural human hairs and does not include any chemicals and/or man-made materials. The shaker hair is statically charged with negative electricity to not only allow easy application to the affected areas, but also cling to the user's scalp and existing hair. Thus, the shaker hair creates root lift and substantial kickstand support to the existing long hair of the user, and helps the user with desired styling. Further, an innovative method of making the all-natural human shaker hair is provided. The method prepares the shaker hair by cutting natural human hairs into hair granules and charging the hair granules with a charging machine. The resulting shaker hair charged with statically negative charge is placed into hair shakers and ready for use.

Pro-toothpaste compositions formulated to receive a volume of allergen solution to provide toothpastes that exhibit efficacy for oral mucosal immunotherapy (OMIT) and acceptable consumer and product stability properties, along with kits of pro-toothpaste, allergen/extracts of allergens, and optionally compounding means and/or specialized toothbrushes are provided. Toothpastes suitable and effective for OMIT and methods for managing allergic symptoms and for reducing risk of allergy in people without symptoms employing the pro-toothpastes, toothpastes and kits of the invention are also disclosed.